VANCOUVER, Wash. and NEW YORK, Jan. 8, 2023 (GLOBE NEWSWIRE) — Absci Corporation ABSIa company developing AI generative medicines, announced today that the company will participate in the upcoming 41st^St Annual JP Morgan Healthcare Conference in San Francisco, CA.

The Absci management is expected to present itself on Tuesday, January 10th^th at 5:15 p.m. Pacific Time (8:15 p.m. Eastern Time). This presentation time has been updated from a previous announcement to reflect the current schedule. Interested parties can access a live and archived webcast of the presentation on the Company’s Investor Relations website at: investors.absci.com.

About Absci

Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ platform to identify novel drug targets, discover optimal biotherapeutic candidates and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators work with us to develop the next generation of protein-based drugs, including Bionic™ proteins containing non-standard amino acids and other novel drug designs that may be impossible to manufacture with other technologies. Our goal is to enable the development of better medicines Translate ideas into drugs™. For more information visit www.absci.com and follow us on social media: Twitter: @AbscibioLinkedIn: @absciand subscribe to ours Absci YouTube channel.

Availability of more information about Absci

Investors and others should note that we routinely communicate with investors and the public through our website (www.absci.com) and our investor relations website (investors.absci.com), including by posting investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites, as well as on Twitter, LinkedIn and YouTube. The information we publish on these websites and social media…